Monday, March 25, 2013

Shionogi Receives Marketing and Manufacturing Approval of a Drug for Lipodystrophy, "M ETRELEPTIN for Subcutaneous Injection

 Shionogi & Co., Ltd. today announced thatit received marketingand manufacturing approval of recombinant human leptin, "METRELEPTIN for subcutaneous injection 11.25 mg 'SHIONOGI'"
(generic name: metreleptin) for lipodystrophy on March 25,2013 in Japan. Metreleptin was 
in-licensed by Shionogi from US-based AmylinPharmaceuticals, LLC., a subsidiary
of Bristol-Myers Squibb Company currently. 
 
Lipodystrophy is a rare and life-threatening disorder characterized by a lack of the
subcutaneous fat tissue required for normal metabolic function, and is highly correlated to
metabolic abnormalities such as severe diabetes, hypertriglyceridemia and fatty liver disease



Enter your email address:


Delivered by FeedBurner